I
nflammation is a major contributor to the pathophysiology and outcome of cerebral ischemia. The proinflammatory cytokine IL-1 (interleukin-1) is upregulated rapidly in experimental stroke and worsens ischemic injury in preclinical models of cerebral ischemia.
1 IL-1 induces peripheral inflammatory markers, such as interleukin-6 (IL-6), which are associated with worse prognosis after ischemic stroke. 2 The endogenous IL-1 receptor antagonist (IL-1Ra) blocks all known actions of IL-1 by competitively inhibiting the IL-1 receptor 1, without any reported agonist activity. 3 IL-1Ra markedly attenuates experimental brain injury in experimental cerebral ischemia, showing efficacy in aged and comorbid animals, when administered peripherally by subcutaneous or intravenous routes and with delayed administration. 1 The efficacy of IL-1Ra in experimental middle cerebral artery occlusion has been reproduced in a cross-laboratory study using a range of outcome measures, including longer-term functional recovery. 4 A recently updated meta-analysis of preclinical stroke studies showed that IL-1Ra treatment reduced infarct volume by 36% in pooled data from 1283 animals. 5 We have reported previously that intravenous IL-1Ra administered for 72 hours in a placebo-controlled phase 2 study of patients with acute stroke was safe and significantly reduced plasma inflammatory markers. 6 Intravenous IL-1Ra penetrated cerebrospinal fluid at experimentally therapeutic concentrations in patients with acute aneurysmal subarachnoid hemorrhage (aSAH) 7, 8 and reduced cerebrospinal fluid and plasma IL-6 concentrations. 9 IL-1Ra is now available as a commercial subcutaneous formulation used to treat rheumatoid arthritis, which is cheaper and more practical to administer. After pharmacokinetic modeling of subcutaneous treatment, based on therapeutic concentrations of intravenous IL-Ra, we recently undertook a phase 2 trial of subcutaneous IL-1Ra in acute aSAH in which subcutaneous IL-1Ra was safe and significantly reduced plasma IL-6 and CRP (C-reactive protein) concentrations. 10 Our previous trial of intravenous IL-1Ra in ischemic stroke was undertaken before the UK license and therefore widespread clinical use of alteplase in the United Kingdom. In the present study, we investigated whether subcutaneous IL-1Ra reduces the peripheral inflammatory response in acute ischemic stroke, alongside standard of care thrombolysis when clinically indicated. Our primary objective was to determine the effect of subcutaneous IL-1Ra on plasma IL-6 to day 3. Secondary objectives included obtaining exploratory clinical outcome data to inform subsequent phase 3 trial design.
Methods
In line with American Heart Association Journals' implementation of the Transparency and Openness Promotion, the data that support the findings of this study are available from the corresponding author on reasonable request. 
Design and Setting

Participants
Full eligibility criteria are presented in Table I in the online-only Data Supplement. Patients presenting with confirmed ischemic stroke, aged ≥18 years, with a National Institutes of Health Stroke Scale score between 4 and 26, and within 5 hours of symptom onset were eligible. Baseline National Institutes of Health Stroke Scale, drug history, routine blood tests, and computed tomography head were undertaken as part of urgent clinical assessment and informed eligibility screening. Hyperacute research practitioners recruited participants between 0700 and 2100 7 days a week although a screening log was kept of all potentially eligible patients. If capacity to consent to participation was absent, consent was sought from a personal consultee if available or a professional consultee (a senior clinician independent of the study). Baseline assessment was then completed, including past medical history, modified Rankin Scale (mRS) in the month preceding ictus, vascular risk factors, and vital signs.
Intervention
Participants received 6 doses of either 100 mg subcutaneous recombinant human IL-1Ra (anakinra) or placebo. The first dose was started within 6 hours of symptom onset. Five further doses were administered starting at the next administration time point (0700 or 1900±2 hours), at least 6 hours after the first dose and continued every 12 hours until completion of the 6 doses. This regimen was derived from pharmacokinetic model and tolerability data from Amgen, Inc, subsequently validated in our subcutaneous IL-1Ra trial in aSAH.
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Randomization and Blinding
Randomization (1:1) was undertaken using an independent thirdparty, web-based service, stratified for stroke severity (National Institutes of Health Stroke Scale <13 or ≥13) and intravenous thrombolysis.
Venous Blood for Plasma Inflammatory Markers
Venous blood was drawn before consent in potentially eligible patients, supported by our regulatory approvals, to avoid delays in obtaining the baseline prerandomization sample (day 0). This sample was discarded if patients were not included. Blood was also drawn on days 1, 2, 3, and between days 5 to 7. The day 5 to 7 sample was discontinued after blinded review by the Trial Steering Committee after recruitment of the first 58 participants as it had only been obtained in 51% of participants (largely because of participant repatriation to their base hospital after day 3).
Processing and Analyses of Blood Samples
Venous blood was processed and analyzed at Salford Royal NHS Foundation Trust. Blood was collected in EDTA, centrifuged at 2000g at 4°C for 15 minutes, and the plasma frozen at −70°C. Plasma IL-6 and IL-1Ra were measured using ELISA, and CRP and von-Willebrand Factor (vWF) were measured in a duplex assay using Luminex bead technology (see online-only Data Supplement). Laboratory staff were blinded to treatment allocation, except for the individual measuring plasma IL-1Ra. The concentrations of IL-6, CRP, and vWF were transformed using the natural logarithm before analysis.
Outcomes
The primary outcome measure was the area under the curve for the log-transformed concentration of plasma IL-6 between day 1 and day 3. Only participants with a prerandomization sample (day 0) and at least 2 of the 3 subsequent blood samples (day 1, 2, or 3) were eligible for the primary analysis. Laboratory secondary outcomes were the area under the curve for plasma log(CRP) and log(vWF). Clinical blood tests and other investigations were undertaken at the discretion of the clinical team and reviewed by the research team. Serious adverse events and adverse events were recorded daily to day 3 and also at day 30 (±7 days). All brain imaging was reported by neuroradiologists independent of the study, who were blinded to test treatment allocation. Hemorrhagic transformation was classified using the European Cooperative Acute Stroke Study criteria, 11 that is, hemorrhagic infarction 1 or 2 and parenchymal hemorrhage 1 or 2. The clinical secondary outcome was the mRS at 3 months, undertaken by a single, trained rater blinded to treatment allocation, either face-toface or by telephone.
Sample Size
Our previous phase 2 trial of intravenous IL-1Ra in patients with acute ischemic stroke showed a difference (SD) in log(CRP) of 0.8 (1.0) at 3 days. 6 Based on these data, 30 patients were required per group for 80% power at the 5% significance level to detect a difference of 0.75 SD in the primary outcome. We, therefore, aimed to recruit up to 80 patients in total to allow for loss to follow-up. We also considered that complete 3-month mRS data on 50 participants would be adequate for estimation of parameters to inform a phase 3 sample size calculation.
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Statistical Methods
All analyses were prespecified in a statistical analysis plan before study completion and unblinding of the data set. Demographic and clinical data at baseline were tabulated by allocated test treatment. The primary analysis used linear regression to control for the randomization stratification criteria and for the baseline value of log(IL-6). Where one of the day 1 to day 3 blood samples was unavailable, imputation was undertaken. The fitted value from linear regression of log(IL-6) on "day" was substituted for the missing value. The assumption of linearity for this time period was assessed graphically but was anticipated to be reasonable based on our previous aSAH study data. These linear regression analyses were repeated for plasma CRP and vWF but adjusting each for its own baseline value. Ordinal logistic regression was used to analyze mRS, adjusting for the stratification variables. We also undertook mediation analysis to explore the hypothesized causal pathway from treatment (IL-1Ra) through mediator (area under the curve log[IL-6]) to outcome (mRS). 12 As this method is not yet developed for ordinal outcomes, we first dichotomized the mRS as 0 to 2 versus 3 to 6. All analyses were undertaken in Stata version 14.
Results
Of 742 patients screened between March 22, 2014, and October 31, 2016, 207 met the eligibility criteria. Of these, 118 were approached and 80 (68%) were recruited ( Figure 1 ). One patient deteriorated rapidly after randomization (to IL-1Ra) and was withdrawn before receiving any test treatment. Baseline characteristics of the recruited patients are shown in the Table. Although the majority of participants (73%) received intravenous alteplase, the onset to needle time was shorter in the placebo group. The interval from stroke onset to initiation of test treatment was not different between the 2 allocation groups.
Sixty-three participants (n=35 placebo; n=28 IL-1Ra) had sufficient blood samples for the primary analysis (Figure 1) , thereby meeting our planned sample size. IL-1Ra prevented the rise in plasma IL-6 concentrations observed in the placebo group ( Figure 2A ) and significantly reduced the area under the curve plasma log(IL-6; Figure 3A ) in the adjusted linear regression analyses (P<0.001; Table II in the online-only Data Supplement). Post hoc sensitivity analyses taking into account imputation, and its potential interaction with the treatment effect, made no substantive difference to these findings (Table  III in the online-only Data Supplement). A similar effect of IL-1Ra treatment was observed for plasma CRP concentrations (Figures 2B and 3B ; Table IV in the online-only Data Supplement), but there was no observed difference in plasma vWF concentrations (Figures 2C and 3C ).
There were 16 serious adverse events in 14 patients (11 serious adverse events in 9 allocated placebo and 5 serious adverse events in 5 allocated IL-1Ra) and 22 
Final 3-month mRS was available in 75 participants (94%). Mortality was similar between the allocation groups ( Figure 1) . More participants achieved a 3-month mRS of 0 to 2 in the placebo group (51%) compared with the IL-1Ra group (42%; Figure IA in the online-only Data Supplement). In the adjusted ordinal logistic regression analyses, allocation to IL-1Ra was not associated with a favorable outcome on the mRS: odds ratio (95% confidence interval)=0.67 (0.29-1.52), P=0.34. Further adjustment for prestroke mRS and thrombolysis onset to needle time in the regression model did not materially alter these findings (data not shown).
The mediation analysis ( Figure 4 ) suggested that while taking baseline plasma IL-6 concentrations into account, IL-1Ra reduced the odds of a poor mRS outcome via the expected mechanism of reducing plasma IL-6 (odds ratio [95% confidence interval]=0.42 [0.19-0.94]; P=0.04). By contrast, there was a negative residual effect, in that IL-1Ra increased the odds of a poor mRS score (odds ratio [95% confidence interval]=4.58 [1.19-17 .71]; P=0.03) by some other pathway or mechanism. Given that the majority of patients received thrombolysis, we undertook further post hoc analyses adjusting the mediation approach for additional covariates, including baseline severity and thrombolysis in various categorizations (eg, early versus late). None of these exploratory analyses substantively affected the findings.
Discussion
IL-1 mediates inflammatory and immune responses in both the central nervous system and periphery which are strongly implicated in cerebral ischemic injury and clinical outcome. 1 As downstream biomarkers of IL-1 induction, elevated plasma IL-6 and CRP concentrations are consistently predictive of poor clinical outcome in the acute phase of ischemic stroke. 2, 13, 14 Here, we have shown that treatment with subcutaneous IL-1Ra in hyperacute ischemic stroke significantly reduced plasma concentrations of IL-6 and CRP for the first 3 days. These findings are consistent with reduced concentrations of these plasma inflammatory markers observed in our previous studies of subcutaneous IL-1Ra in aSAH 10 and intravenous IL-1Ra in acute stroke and aSAH. 6, 9 To our knowledge, such robust and consistent reduction of downstream peripheral inflammatory markers has not been demonstrated with other candidate anti-inflammatory drugs for acute stroke. 15 The mechanisms by which peripherally administered IL-1Ra reduces plasma IL-6 concentrations are yet to be fully characterized. IL-1 and IL-6 are upregulated rapidly in the ischemic hemisphere after middle cerebral artery occlusion, [16] [17] [18] and their concentrations are elevated acutely in the cerebrospinal fluid of patients with ischemic stroke. 19 Elevated plasma IL-6 concentrations precede those in the ischemic hemisphere in experimental middle cerebral artery occlusion, 20 yet production of IL-1 and IL-6 by peripheral blood leucocytes within hours of stroke onset is negligible. 21 Hence, as yet undetermined, peripheral cellular sources may produce IL-6 in response to cerebral ischemia. Peripherally administered IL-1Ra crosses the blood-cerebrospinal fluid barrier and blood-brain barrier after SAH, 22 and it is, therefore, likely that subcutaneous IL-1Ra reduces plasma IL-6 by inhibiting its induction by IL-1 both in the ischemic brain and in the peripheral circulation.
We were surprised to observe a 95% confidence interval for clinical outcome that excluded a major benefit of treatment with IL-1Ra. This contrasts with our previous studies both of subcutaneous IL-1Ra in aSAH and intravenous IL-1Ra in stroke. Indeed, IL-1Ra in aSAH has now progressed to a multicenter phase 3 trial (NCT03249207). A post hoc individual participant data meta-analysis combining our present data in ischemic stroke patients with our previous phase 2 trial investigating intravenous IL-1Ra in a similar population ( Figure II in the online-only Data Supplement) did not alter this conclusion. Although differences in the distribution of mRS scores between IL-1Ra and placebo were observed when comparing the previous intravenous trial and present subcutaneous trial ( Figure I in the online-only Data Supplement), these should be interpreted cautiously as secondary analyses in relatively small sample sizes.
We used mediation analysis, which to our knowledge is a novel approach in acute stroke trials. The mediation analysis suggested that IL-1Ra improved the odds of a favorable clinical outcome by reducing plasma IL-6 concentrations (the mediator variable), indicative of upstream IL-1 blockade, as expected. However, the mediation analysis revealed an additional, residual negative pathway with IL-1Ra treatment, contributing to overall clinical outcome. Although these exploratory secondary analyses need to be interpreted with caution, they are useful in hypothesis generation when considering future studies of IL-1Ra in ischemic stroke. Similar mediation analyses in our recent aSAH trial also confirmed a favorable effect of IL-1Ra on clinical outcome through lowering plasma IL-6 concentrations but with no residual negative effect. Similarly, reanalysis of our intravenous IL-1Ra in stroke study (data not published) did not suggest any residual effect. One clear difference is that this is the first of our IL-1Ra studies in which thrombolysis has been administered. The importance of potential interactions between candidate treatments and thrombolysis in acute stroke trials has previously been highlighted. 23 Tissue-type plasminogen activator (tPA) has a range of deleterious effects in cerebral ischemia, several of which are independent of its fibrinolytic activity. 24 There are few data on combined treatment with IL-1Ra plus tPA in preclinical studies of ischemic stroke, 4 but there is no suggestion of any adverse interaction. IL-1Ra might be expected to augment the beneficial effects of tPA treatment by reducing the deleterious effects of reperfusion injury, tPA-induced neurotoxicity, and neuroinflammation. 25, 26 Conversely, IL-1 increases levels of endogenous plasminogen activator inhibitor-1, 27 the principal physiological inhibitor of tPA. IL-1 blockade combined with tPA in ischemic stroke could, therefore, potentiate excessive fibrinolysis or other deleterious effects. We observed no differences in hemorrhagic transformation, but as this is a relatively small sample size, a difference cannot be excluded from our present data. Finally, the transcription factor high mobility group box-1, which is upregulated rapidly after cerebral ischemia, 28 augments tPA-induced fibrinolysis and protects against tPA-induced neurotoxicity and blood-brain barrier damage in experimental stroke. 29 As IL-1 upregulates high mobility group box-1 in mononuclear cells, 30 IL-1 blockade might impact negatively on these apparent protective effects of high mobility group box-1 in the setting of thrombolysis with tPA.
Our study has several strengths. It was designed in line with consensus recommendations for phase 2 clinical trials of candidate drugs for acute ischemic stroke. 31, 32 Our dosing regimen was based on robust pharmacokinetic modeling and known preclinical therapeutic concentrations. A relevant surrogate outcome measure was selected for the primary outcome, measured using well-established methods and confirming proof of concept. Our design allowed us to test IL-1Ra alongside thrombolysis with intravenous alteplase to explore combination therapy. 23, 32 We achieved our planned sample size for the primary analyses and used ordinal analysis of the mRS secondary outcome. Mediation analysis enabled hypothesis generation to inform future experimental and clinical studies. We also acknowledge several limitations of our trial. Recruitment was limited to a single center which may have implications for generalizability. Inclusion of patients receiving intravenous thrombolysis as part of urgent clinical care is likely to have introduced inevitable delays in administration of test treatment. However, although onset to test treatment was on average 4.4 hours, we still observed significant reductions in plasma IL-6. Our study design did not include evaluation of pre-and post-treatment angiography to determine site of arterial occlusion and whether spontaneous or fibrinolytic reperfusion occurred in the context of allocation to IL-1Ra or placebo. Likewise, we did not undertake preand post-treatment magnetic resonance imaging to evaluate infarct expansion, edema, or infarct volume. These may have provided useful insights in secondary analyses although interpretation is likely to have been limited given our relatively small sample size. Our regional clinical service model meant that some participating patients were repatriated to their local hospital before completion of blood sampling, which limited availability of the day 5 to 7 sample. Finally, the mediation analyses were necessarily restricted to those patients with sufficient plasma IL-6, which limited sample size further.
Summary
We have demonstrated that subcutaneous IL-1Ra significantly reduced plasma inflammatory markers that are known to be associated with a worse outcome after ischemic stroke. In hypothesis-generating mediation analyses, subcutaneous IL-1Ra positively influenced outcome by the expected mechanism of reducing plasma concentrations of IL-6, but there was a residual negative effect that may represent an interaction with alteplase. Further experimental stroke studies are required to fully investigate efficacy and mechanisms of IL-1Ra in the presence of thrombolytic agents.
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